Analytik Jena Acquires 100% Stake in Biometra GmbH, Göttingen

• Well-known player in the growing market segment substantially strengthens life sciences portfolio of Analytik Jena
• Innovative products of Analytik Jena meet a well-positioned worldwide distribution network in over 60 countries

Jena/Goettingen, 30 April 2009 – Analytik Jena AG (Frankfurt, Prime Standard: AJA), a manufacturer and distributor of analytical and bioanalytical systems for industrial and scientific applications, today announced signing of deal for the acquisition of Biometra GmbH.

Biometra develops and provides innovative products in the broad field of thermo-cycling, electrophoresis, blotting, gel imaging and hybridization. The company was founded in 1985 and is one of the pioneers in the field of DNA polymerase chain reaction (PCR) technology. The Biometra PCR instruments are well positioned worldwide. Sales in recent years have been steady around 9.0 million EUR with good profitability. The integration of Biometra increases the competence of Analytik Jena in the field of DNA analysis through additional new technologies, and significantly strengthens the distribution structure. As a company with a longstanding tradition Biometra has a well-established distribution network. Through the acquisition Analytik Jena boosts its presence especially in Asia and Europe. In addition, it increases the direct distribution channels in the home market of Germany. Biometra has 55 employees.

Analytik Jena will acquire 100% of the shares of Biometra GmbH on 11.05.2009, based on an all cash transaction. The shares will be acquired from Whatman GmbH. Financial terms were not disclosed.

The product portfolios of the two companies are complementary. Analytik Jena also develops and distributes products for thermocycling, under a patented process, which enables an extremely rapid DNA reproduction. This is also true for other products, such as DNA-kits, DNA-chip Photometer, gel electrophoresis or gel-documentation. Hence, further innovative product developments can be optimized and faster implemented. Those synergies strengthen and accelerate the development of further innovative products.

Concerning the acquisition Klaus Berka, CEO of Analytik Jena AG, said the following: "The robust financial resources and sound economic development of Analytik Jena AG enables us to continue our consistent growth strategy. With the acquisition of Biometra, we reach a new stage in the implementation of our strategy for the completion and extension of our technology platforms and our know-how in the field of life sciences. Analytik Jena AG extends its portfolio with an established, globally recognized company with outstanding products and a wide spanned distribution structure."